Today we reported positive interim Phase 1 data for our #mRNA based #COVID19 #vaccine candidate: #CVnCoV demonstrated a balanced immune response and was well tolerated across all tested doses.
Learn more: https://t.co/N1cz5qRydf#CVAC #SARSCoV2 #globalhealth #biotech pic.twitter.com/fXChRfb3Mj— CureVac (@CureVacRNA) November 2, 2020
https://twitter.com/CureVacRNA/status/1319603240707756034
Reading recommendation! Find out more about our #IPO from our VP Investor Relations Dr. Sarah Fakih talking to @IRMagazine: “It was a very energized kind of environment”, she recalls. “I reflect on that experience as an exhilarating time.” https://t.co/bAeiFqUMNn#CVAC #NASDAQ
— CureVac (@CureVacRNA) October 20, 2020
We are proud to announce that @FierceBiotech has named us as one of its “Fierce 15” #Biotech Companies of 2020. We highly appreciate this award as recognition of our efforts to create transformative #mRNA-based medicines to protect and improve people’s lives around the globe. pic.twitter.com/h1ieH6e3Vr
— CureVac (@CureVacRNA) September 28, 2020
About one month ago, we successfully joined @Nasdaq and became part of the international #biotech scene listed there.
To everyone at CureVac, to the clinicians and to the shareholders: Thank you for your support and believing in us.#CVAC #theRNApeople #CureVac #IPO #NasdaqListed pic.twitter.com/S4stzO7UVr— CureVac (@CureVacRNA) September 14, 2020
CureVac´s Technology in Berlin: Tesla CEO @elonmusk explaining CureVac´s cooperation with Tesla Grohmann Automation on the development of The RNA Printer® during the @cducsubt meeting. https://t.co/APt3zt3EhJ
— CureVac (@CureVacRNA) September 3, 2020
CureVac – Revolutionizing #mRNA for Life! Our life as a public company started today. We are now trading on @Nasdaq under the ticker #CVAC. Thank you to the #CureVac team – we couldn’t be here without you! #CureVacIPO #IPO #theRNApeople #NasdaqListed
© picture alliance/dpa pic.twitter.com/fgZZdFijdx
— CureVac (@CureVacRNA) August 14, 2020
We are proud to announce that @GSK and CureVac signed a strategic collaboration agreement for the research, development, manufacturing and commercialization of up to five #mRNA-based #vaccines and monoclonal #antibodies.
👉https://t.co/1VvqLei1hN©picture alliance/dpa pic.twitter.com/3GNk845Nvd
— CureVac (@CureVacRNA) July 20, 2020
Today, the @EIB and CureVac entered into a €75 million loan agreement to support our ongoing development of #vaccines against infectious diseases and the expansion of our manufacturing capabilities.
👉 https://t.co/6u2DypBDjz pic.twitter.com/NHoTV7Of8i— CureVac (@CureVacRNA) July 6, 2020
Next milestone reached: We are very pleased to announce that @PEI_Germany and Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial of our #mRNA based #vaccine candidate against #COVID19.
Press release 👉 https://t.co/rcXY0p7i1h pic.twitter.com/n4krzxgnut— CureVac (@CureVacRNA) June 17, 2020
The German Federal Government has decided to invest 300 million Euros in CureVac as part of the Corona Economic Stimulus and Future Technologies Package. For more information, please visit https://t.co/MeOP8FbfEj#dievini #BMWi #CureVac #mRNA #biotechnology #Konjunkturpaket
— CureVac (@CureVacRNA) June 15, 2020
Today, we announced positive pre-clinical results at a low dose for our #mRNA based lead #vaccine candidate against the novel #Coronavirus. We intend to initiate the first clinical trial in humans in June 2020.
For more information, please click here 👇https://t.co/hxooxdYzo2
— CureVac (@CureVacRNA) May 14, 2020
“We are stronger together, all united against the coronavirus”. Dr. Lidia Oostvogels, Head of Infectious Diseases on joining the #Coronavirus #GlobalResponse
👉 https://t.co/HD6zyzRbXo#UnitedAgainstCoronavirus #StrongerTogether #COVID19 https://t.co/bI9i3jveet— CureVac (@CureVacRNA) May 4, 2020
What does our development of a #mRNA based #vaccine against the #coronavirus look like? Find out the answer & more in the #podcast episode “The Race for a Vaccine” of @nytimes where our Head of Infectious Diseases is speaking – tune in now!
👉 https://t.co/XVUzoe6ATZ— CureVac (@CureVacRNA) April 2, 2020
We had a very supportive call with @vonderleyen and @GabrielMariya speaking about our #mRNA vaccine approach possibly protecting people worldwide from #coronavirus https://t.co/5E3ykl79tT
— CureVac (@CureVacRNA) March 16, 2020
CureVac focuses on the development of a mRNA-based coronavirus vaccine to protect people worldwide. We abstain from commenting on speculations and rejects allegations about offers for acquisition of our company or our technology.
To our press release: https://t.co/DQGWgdcUJc— CureVac (@CureVacRNA) March 15, 2020
Follow our CEO Daniel Menichella illustrating CureVac´s activities regarding a vaccine candidate against the novel #virus #COVID19 on CNBC´s show “Squawk on the Street”.
#coronavirus #mRNA #vaccine #globalhealth— CureVac (@CureVacRNA) February 17, 2020
We extend our cooperation with @CEPIvaccines to rapidly advance a #mRNA based vaccine candidate against the novel #coronavirus into clinical testing 🧬🌍#globalhealth #2019nCoV #outbreak #Epidemic
👉https://t.co/kOpzuniK3Z pic.twitter.com/uf90QWzsRX
— CureVac (@CureVacRNA) January 31, 2020
CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study https://t.co/pKgz2qqyg2
CureVac berichtet positive Ergebnisse aus niedrig dosierter 1 µg Phase-1-Studie mit Tollwut-Impfstoff https://t.co/n5tm7QGMnR pic.twitter.com/826YY1aIjh
— CureVac (@CureVacRNA) January 7, 2020
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics https://t.co/0LW5Er8a7Z
Genmab und CureVac gehen strategische Partnerschaft zur Entwicklung von mRNA-basierten Antikörper-Therapeutika ein https://t.co/NAjhbVWWDW
— CureVac (@CureVacRNA) December 19, 2019
CureVac Enters into an Exclusive Collaborative Research Agreement for Discovery Research in mRNA-based Lung Therapy Candidates with Yale University https://t.co/Cv60bNIoKM
— CureVac (@CureVacRNA) August 13, 2019
#CEPI awards US$ 34M contract to #CureVac to advance The RNA Printer™https://t.co/sFxvZTwB6N
— CureVac (@CureVacRNA) February 27, 2019
The chairman of #biopharma company #CureVac's Supervisory Board @ingmarhoerr on the current #mRNA #therapeutics #market at @GENbio: "The Race Is On: What mRNA Product Will Reach the Market First?"https://t.co/D18mhz0avv pic.twitter.com/xakbIGtCVi
— CureVac (@CureVacRNA) February 20, 2019
#Biopharma company #CureVac Announces U.S. #Patent Grant for #mRNA #Vaccination of #Infants Against #RSV – Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected #Respiratory Condition: https://t.co/lkUqUMxbQN #VaccinesWork #ResearchSavesLives
— CureVac (@CureVacRNA) January 8, 2019
#CureVac to Present Preliminary Phase I Data on CV8102, an #Intratumoral #RNA-based #CancerTherapy, at the 2018 Society for Immunotherapy of Cancer Annual Meeting this Friday in #WashingtonDC: https://t.co/Lsr7eiFTIc@sitcancer
— CureVac (@CureVacRNA) November 7, 2018
“How to develop a new #vaccine or #therapeutic modality in a skeptical environment, with little #biotech experience, limited #resources and limited #capital.” Read #biopharma-company #CureVac’s history in @NatureBiotech: https://t.co/2AYsyPgivT
— CureVac (@CureVacRNA) May 3, 2018
.@BillGates builds on #RNA technologies for the development of a universal #flu #vaccine and names #CureVac – interesting article on @statnews https://t.co/StcFEK7Ufe
— CureVac (@CureVacRNA) April 30, 2018
We are excited to welcome the highly competent and internationally experienced leader Dr. Alan Kimura as head of our new department Rare Diseases. With this reorganization, we unite the areas Molecular Therapies and Eye & Lung to strengthen our activities across these fields. pic.twitter.com/wwako4RQse
— CureVac (@CureVacRNA) February 26, 2020
Fueled by proprietary ribonucleic acid technology and two decades of science excellence, @CureVacRNA is dedicated to creating novel prophylactic and therapeutics treatments that enable the body to make its own drugs.#CureVacIPO #NasdaqListed $CVAC #theRNAPeople pic.twitter.com/14Ex7yk10r
— Nasdaq (@Nasdaq) August 14, 2020
Eisai Exec Voliotis Joins CureVac as Chief Development Officer https://t.co/7lkgxPrmqr
— TheBiotechTimes (@BiotechTimes) January 30, 2019
How will the EU remain attractive for innovation in the global market – discussed by Lowri Evans, Ingmar Hoerr, Peteris Zilgalvis & Petra Püchner #WigiEU @EU_Growth @DSMeu @WM_BW @H2020SME @CureVacAG @ingmarhoerr @PZilgalvis @SEZ_Europ pic.twitter.com/D7q697s4na
— Nicole Gutknecht 🇪🇺 (@NMuessigmann) January 21, 2019
CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference https://t.co/JkcAQFiSTR
— GNWLive (@GNWLive) November 21, 2018
Q&A: mRNA’s place in vaccine manufacturing with CureVac https://t.co/561UfjnqSW #onmedic #ehealth #pharma
— onmedic global (@onmedicglobal) November 19, 2018
CureVac to Present Preliminary Phase I Data on CV8102 an Intratumoral RNAbased Cancer Therapy at the Society for Immunotherapy of Cancers 33rd Annual Meeting: Data to be presented includes CV8102 as a single agent and in combination with antiPD1 therapy… https://t.co/xJlHGtmZdC
— Colorectal Cancer (@Colorectal_bio) November 7, 2018
News of Note—Flu vaccines, CureVac and more https://t.co/W81mdIUoCh #pharma pic.twitter.com/ziepPhoywh
— Kevin Kurbs (@KKurbs) October 31, 2018
Welcoming new names to the list of billion-euro biotechs! 💪💸#biotech #lifesciences@Genmab @MorphoSys @GalapagosNV @gwpharma @Idorsia @EvotecAG @OxfordNano @CureVacAG @Immunocore @DBVTechnologies @cellectis https://t.co/m0yN29tlrJ
— Labiotech.eu (@Labiotech_eu) October 29, 2018
CureVac initiates rabies vaccine trial https://t.co/nj76pRaHTg
— Анатолій АНЧИШКІН (@deltakr) October 28, 2018
My colleague @ChrisJElias and I are in #Berlin for #WHS2018 and #GrandChallenges. Inspired by the innovative and determined energy all around us, we wrote an article explaining why Germany is an emerging leader in global health. https://t.co/hhvP1Nyo3b
— Trevor Mundel (@trevormundel) October 17, 2018
Transitioning a biological discovery from bench to business is difficult enough for a well-conceived and researched technology (…). @ingmarhoerr, who founded @CureVacAG in 2000, shares his thoughts about building a biotech startup.#biotech #startuphttps://t.co/FEA6qiNQUC pic.twitter.com/LeRssDFcQ2
— infosharepl (@infosharepl) July 26, 2018
Bill Gates on why investing $10 billion in the development and delivery of new medicines beats any market bet he could have made https://t.co/uBmM5PV2i4
— The Wall Street Journal (@WSJ) January 19, 2019
Breaking News: The Nobel Prize in Medicine recognized breakthroughs in using the immune system to attack cancer. It went to James P. Allison and Tasuku Honjo. https://t.co/vnWpRGRebt
— The New York Times (@nytimes) October 1, 2018
In @NYTOpinion,
Melinda Wenner Moyer writes, "Bad vaccine science does not deserve a forum — and much of the research cited by anti-vaccine activists is very bad indeed. But good science needs to be heard even if some people will twist its meaning." https://t.co/c9DdYHkCJ7— The New York Times (@nytimes) August 5, 2018
May 18 is HIV Vaccine Awareness Day. Help us celebrate the promise and progress of a vaccine: https://t.co/4ztmlWkMGB #VaccinesWork #EndAIDS4Good #HVAD2018 pic.twitter.com/NHZCTg2xoI
— IAVI (@IAVI) May 14, 2018
Coronavirus vaccine update: CureVac shows immune response in early trials (11/03/2020) | @bsindia
When will the #coronavirus vaccine be ready?
CureVac, a Tübingen-based company in Germany is one of a number of biotechcompanies working towards finding the answer.https://t.co/q5b3RJ7twP pic.twitter.com/SH2O6o7kbG— GIC Africa (@GermanyInAfrica) October 30, 2020
CureVac said its potential vaccine, known as CVnCoV, was generally well tolerated and results strongly supported the company's plans to launch the final stage of testing on humans before the end of the year https://t.co/zGVnPdDyUC
— Mint (@livemint) November 2, 2020
A coronavirus vaccine under development from CureVac shows a good immune response in early trials, validating the biotech company’s 20 years of research into messenger RNA https://t.co/KsvZQWVwnp
— Bloomberg (@business) November 2, 2020
CureVac links COVID-19 vaccine to immune response, setting it up to enter pivotal trial https://t.co/h40UUziWef pic.twitter.com/o8a3TaJzjX
— BioCalifornia (@BioCalifornia) November 2, 2020
German vaccine maker CureVac said that interim results from early trials showed that its investigational Covid-19 vaccine candidate, CvnCoV, appeared safe and triggered immune response among volunteers.https://t.co/H2getZQXSi
— News18.com (@news18dotcom) November 2, 2020
CureVac says coronavirus vaccine trial produces immune response in people https://t.co/Sq9DMjnKqZ
— British Herald (@BritishHeraldUK) November 2, 2020
CureVac's COVID-19 vaccine triggers immune response in Phase I trial https://t.co/BSUHmYjlVt pic.twitter.com/YML4lKmW27
— Reuters (@Reuters) November 2, 2020
CureVac's COVID-19 vaccine triggers immune response in Phase I trial https://t.co/SzWt2Adj4w
— Haaretz.com (@haaretzcom) November 2, 2020
CureVac Covid-19 vaccine induces immune response in early trial https://t.co/ayIU5Vc28v
— Khaleej Times (@khaleejtimes) November 2, 2020
CureVac’s experimental Covid-19 vaccine triggered an immune response in humans, putting the German biotech company on track to start mass testing this yearhttps://t.co/KeryNhcAiF
— Hindustan Times (@htTweets) November 2, 2020
CureVac’s experimental Covid-19 vaccine triggered an immune response in humans, putting the German biotech company on track to start mass testing this yearhttps://t.co/KeryNgUZr7
— Hindustan Times (@htTweets) November 2, 2020
#COVID19 vaccine update: From CureVac candidate’s immune response in humans to unwilling Russianshttps://t.co/JWNpuqBH4u pic.twitter.com/HGu7nT1EM6
— Hindustan Times (@htTweets) November 3, 2020
#COVID19vaccine tracker: German CureVac shows an immune response, Aspen Pharmacare and J&J sign pact to make vaccine in South Africa https://t.co/l8yE4R0XZn pic.twitter.com/ZLhmrhDkGn
— Business Insider India🇮🇳 (@BiIndia) November 3, 2020
CureVac Covid vaccine shows immune response in early trial, on track for advanced trial
Suzi Ring @journosooz reportshttps://t.co/PetS90qObV
— Shekhar Gupta (@ShekharGupta) November 2, 2020
CureVac #CovidVaccine Induces Immune Response In Early Trial https://t.co/lFoBIfmCyg
— OTV (@otvnews) November 2, 2020
Germany's CureVac #COVID19Vaccine Induces Immune Response in Early Human Trialshttps://t.co/A34DkBfdZG
(📸: IANS) pic.twitter.com/EYagKqhV17
— The Weather Channel India (@weatherindia) November 3, 2020
Coronavirus vaccine news: CureVac's vaccine triggers immune response, UK begins review for AstraZeneca's drug https://t.co/NpANVDyk2h via @indiatoday
— K.RAGAVAN.. (@write2ragavan) November 3, 2020
“Our Covid Vaccine Triggered Immune Response In Humans”: CureVac @CureVacRNA #covid19 #covid19updates #vaccineupdates #ImmuneSystem #humantrial #biotech #vaccines https://t.co/hjhkHetrNY
— Healthwire (@HealthwireMedia) November 2, 2020
Study: @CureVacRNA's COVID-19 Vaccine Produces Immune Responses in Healthy Volunteers#biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccine #CureVachttps://t.co/gCw6yWZYWn
— BioSpace (@biospace) November 2, 2020
CureVac aims to launch the final stage of testing the vaccine on 30,000 participants before the end of the year. https://t.co/4jpiLJFTNX@CureVacRNA @gatesfoundation #CovidVaccine
— Truescoopnews (@TrueScoopNews) November 2, 2020
Promising news from ZAGENO customer, @CureVacRNA – CureVac’s COVID-19 vaccine shows immune response in Phase 1 trial https://t.co/4y7mM5go5r by @marketwatch
— ZAGENO (@ZAGENOteam) November 2, 2020
.@CureVacRNA trails its competitors in the #Covid19 vaccine race, but the German #biotech is keeping up with the pace. $CVAC execs say they saw enough evidence to take the #vaccine to Phase IIb/III before the end of the year.$MRNA $BNTX $ARCT $TBIO https://t.co/4HPIGZBjWb
— Corona Stocks (@CoronaStocks) November 2, 2020
: CureVac’s COVID-19 vaccine shows immune response in Phase 1 trial German biotech CureVac said advanced clinical trials are on track to launch by the end of 2020.
https://t.co/BEFYD6Megf pic.twitter.com/ZpSezgxDMB
— of today (@_oftoday_) November 2, 2020
#CureVac posts an upbeat take on interim PhI #Covid-19 #vaccine results, with a pivotal study looming. But you'll have to wait on data – https://t.co/EhA7lWQqZ1 @endpts @CureVacRNA
— Plexus Ventures (@PlexusVentures) November 2, 2020
#CureVac Reports Positive Preclinical Data for its #COVID-19 #Vaccine Candidate #CVnCoV https://t.co/o7Z0ndPpNq @Drugscom @CureVacRNA
— Plexus Ventures (@PlexusVentures) October 27, 2020
CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate CVnCoV – https://t.co/XVzaQVMmoo MedNews #pharmatopnews https://t.co/ZZbKzKYQDH
— Pharma Top News (@PharmaTopNews1) October 27, 2020
#VC #investments💰 in #Europe🌍 reached a new #record🏆 of €10.2 billion!😱 Across 1,024 deals in Q3’20 in which @Klarna is leading🥇 followed by @CureVacRNA🥈 @northvolt🥉 and @RevolutApp🏅
Read more👀 in this article https://t.co/mUclnCqnyd#technews #COVID19 #startups @KPMG pic.twitter.com/PspfLC2ZS8
— Silicon Canals – European technology news (@SiliconCanals) October 27, 2020
ICYMI: Here's where Massachusetts drugmakers @moderna_tx, @CureVacRNA and @TranslateBio stand with their #covid19 vaccineshttps://t.co/nHET6qr4B3 $MRNA $CVAC $TBIO
— Allison DeAngelis (@BosBizAllison) October 27, 2020
9/ Finally, exits have been the most muted aspect of the VC ecosystem in 2020 and could reach their lowest level since 2012 by year end.
➡️The five largest exits in Q3 were all IPOs, led by the IPO of @CureVacRNA pic.twitter.com/KG6WFFNcmA
— Sifted (@Siftedeu) October 29, 2020
CureVac is moving ahead with the highest dose of its mRNA-based vaccine, which triggered neutralizing antibodies and early indications of T cell activation in a phase 1 trial, the German shot maker said. https://t.co/9TCXGa9YfF
— Jesús (@rasta_yisus) November 3, 2020
Coronavirus vaccine update: CureVac shows immune response in early trials https://t.co/unDvkRSFjd
— Conrad Lee Spencer-CEO of Peter's Mfg. & Sales Co. (@conradlspencer) November 3, 2020
Good news: CureVac’s corona vaccine seen effective on humans, vaccine may come soon https://t.co/dvA0hvMxUF
— Amol Kote (@amol_kote) November 3, 2020